PMID- 34158077
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20220531
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 19
IP  - 1
DP  - 2021 Jun 22
TI  - CircLRP6 contributes to prostate cancer growth and metastasis by binding to 
      miR-330-5p to up-regulate NRBP1.
PG  - 184
LID - 10.1186/s12957-021-02287-2 [doi]
LID - 184
AB  - BACKGROUND: Circular RNA low-density lipoprotein receptor-related protein 6 
      (circLRP6) is considered as an oncogene in many types of cancers. However, the 
      function and mechanisms of circLRP6 in prostate cancer (PCa) tumorigenesis remain 
      largely undefined. METHODS: Quantitative real-time polymerase chain reaction 
      (qRT-PCR) and western blot assays were conducted to assess the expression of 
      circLRP6, microRNA (miR)-330-5p, and nuclear receptor binding protein 1 (NRBP1). 
      Cell counting kit-8 (CCK-8), colony formation, 5-ethynyl-2'-deoxyuridine (EDU) 
      incorporation, flow cytometry, transwell, wound healing, and western blot assays 
      were performed to detect cell proliferation, apoptosis, and metastasis in vitro. 
      Subcutaneous tumor growth was observed in nude mice to investigate the role of 
      circLRP6 in vivo. The targeting relationship between miR-330-5p and NRBP1 or 
      circLRP6 was verified using dual-luciferase reporter, pull-down, and RNA 
      immunoprecipitation (RIP) assays. Immunohistochemistry was employed to test 
      relative protein expression. RESULTS: CircLRP6 was highly expressed in PCa 
      tissues and cells, knockdown of circLRP6 impaired PCa cell growth and metastasis 
      in vitro by affecting cell proliferation, apoptosis, invasion, migration, and 
      epithelial-mesenchymal transition (EMT). Mechanistic studies showed that circLRP6 
      could competitively bind with miR-330-5p to prevent the degradation of its target 
      gene NRBP1. Rescue assay suggested that miR-330-5p inhibition reversed the 
      inhibitory effects of circLRP6 knockdown on PCa cell growth and metastasis. 
      Moreover, overexpression of miR-330-5p suppressed PCa progression via NRBP1. 
      Notably, tumor formation assay indicated that circLRP6 silencing impeded tumor 
      growth and EMT in vivo. CONCLUSION: Our findings demonstrated that circLRP6 
      promoted PCa tumorigenesis and metastasis through miR-330-5p/NRBP1 axis, 
      suggesting a potential therapeutic target for PCa.
FAU - Qin, Linghui
AU  - Qin L
AD  - Department of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei 
      University of Arts and Science, No. 136, Jingzhou Street, Xiangyang, 441021, 
      Hubei, China.
FAU - Sun, Xiaosong
AU  - Sun X
AD  - Department of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei 
      University of Arts and Science, No. 136, Jingzhou Street, Xiangyang, 441021, 
      Hubei, China.
FAU - Zhou, Fei
AU  - Zhou F
AD  - Department of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei 
      University of Arts and Science, No. 136, Jingzhou Street, Xiangyang, 441021, 
      Hubei, China.
FAU - Liu, Cheng
AU  - Liu C
AD  - Department of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei 
      University of Arts and Science, No. 136, Jingzhou Street, Xiangyang, 441021, 
      Hubei, China. ivncdd@163.com.
LA  - eng
PT  - Journal Article
DEP - 20210622
PL  - England
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
RN  - 0 (MIRN330 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (NRBP1 protein, human)
RN  - 0 (RNA, Circular)
RN  - 0 (Receptors, Cytoplasmic and Nuclear)
RN  - 0 (Vesicular Transport Proteins)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - *MicroRNAs/genetics
MH  - Prognosis
MH  - *Prostatic Neoplasms/genetics
MH  - RNA, Circular/*genetics
MH  - *Receptors, Cytoplasmic and Nuclear/genetics
MH  - *Vesicular Transport Proteins/genetics
PMC - PMC8220703
OTO - NOTNLM
OT  - Growth
OT  - Metastasis
OT  - MiR-330-5p
OT  - NRBP1
OT  - Prostate cancer
OT  - circLRP6
COIS- The authors declare that they have no competing interests.
EDAT- 2021/06/24 06:00
MHDA- 2021/06/25 06:00
PMCR- 2021/06/22
CRDT- 2021/06/23 05:46
PHST- 2021/04/13 00:00 [received]
PHST- 2021/06/04 00:00 [accepted]
PHST- 2021/06/23 05:46 [entrez]
PHST- 2021/06/24 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2021/06/22 00:00 [pmc-release]
AID - 10.1186/s12957-021-02287-2 [pii]
AID - 2287 [pii]
AID - 10.1186/s12957-021-02287-2 [doi]
PST - epublish
SO  - World J Surg Oncol. 2021 Jun 22;19(1):184. doi: 10.1186/s12957-021-02287-2.